{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:00:11Z","timestamp":1794618011343,"version":"4.9.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1053\/j.seminhematol.2023.11.006","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T02:46:03Z","timestamp":1701398763000},"page":"267-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Biological heterogeneity in diffuse large B-cell lymphoma"],"prefix":"10.1053","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-6586","authenticated-orcid":false,"given":"Laura K.","family":"Hilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2023.11.006_bib0001","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0002","series-title":"WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0003","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0004","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0005","series-title":"World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0006","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"de Leval","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0007","article-title":"The genomic and transcriptional landscape of primary central nervous system lymphoma","author":"Radke","year":"2021","journal-title":"MedRxiv Prepr Serv Health Sci"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0008","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1111\/cas.15091","article-title":"Current progress and future perspectives of research on intravascular large B-cell lymphoma","volume":"112","author":"Shimada","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0009","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0010","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0011","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BLC6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0012","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41375-019-0691-6","article-title":"Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC\/BCL2 double-hit","volume":"34","author":"Cucco","year":"2020","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0013","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0014","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0015","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","article-title":"Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma","volume":"26","author":"Fu","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0016","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci U A"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0017","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci U A"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0018","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0019","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1158\/2643-3230.BCD-20-0076","article-title":"PRPS-ST: a protocol-agnostic self-training method for gene expression-based classification of blood cancers","volume":"1","author":"Jiang","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0021","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood.2019002600","article-title":"The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH","volume":"134","author":"Hilton","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0022","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2012-03-415380","article-title":"Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas","volume":"120","author":"Victora","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2023.11.006_bib0023","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0024","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0025","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0026","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0027","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13073-015-0187-6","article-title":"Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas","volume":"7","author":"Sha","year":"2015","journal-title":"Genome Med"},{"issue":"20","key":"10.1053\/j.seminhematol.2023.11.006_bib0028","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1182\/bloodadvances.2023010673","article-title":"Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL","volume":"7","author":"Davies","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0029","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0031","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0032","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0033","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0034","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-13-1482","article-title":"Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies","volume":"19","author":"Coutinho","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0035","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Gutierrez-Garcia","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0036","first-page":"2196","article-title":"The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC","volume":"137","author":"Collinge","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0037","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0038","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2018-05-851154","article-title":"Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens","volume":"132","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0039","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.12045","article-title":"Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome","volume":"159","author":"Barrans","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0040","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.15619","article-title":"Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK's population-based Haematological Malignancy Research Network","volume":"185","author":"Painter","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0041","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0042","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-10-2573","article-title":"Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues","volume":"17","author":"Rimsza","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0043","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2013-06-508937","article-title":"Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens","volume":"122","author":"Masque-Soler","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0044","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.12983","article-title":"Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex(R) system","volume":"167","author":"Collie","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/labinvest.2014.136","article-title":"Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR","volume":"95","author":"Xue","year":"2015","journal-title":"Lab Invest"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0046","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/1078-0432.CCR-14-0357","article-title":"Reproducible, quantitative, and flexible molecular subtyping of clinical DLBCL samples using the NanoString nCounter system","volume":"21","author":"Veldman-Jones","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0047","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jmoldx.2015.01.007","article-title":"Accurate classification of germinal center B-cell-like\/activated B-cell-like diffuse large B-cell lymphoma using a simple and rapid reverse transcriptase-multiplex ligation-dependent probe amplification assay: a CALYM study","volume":"17","author":"Mareschal","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0048","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0049","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","article-title":"Inferring gene expression from cell-free DNA fragmentation profiles","volume":"40","author":"Esfahani","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0050","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0051","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0052","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2023.11.006_bib0053","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.23.00033","article-title":"Differential efficacy from the addition of Bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up","volume":"41","author":"Davies","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0054","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2023.11.006_bib0055","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implications for bias in clinical trials","volume":"36","author":"Maurer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0056","doi-asserted-by":"crossref","first-page":"TPS7572","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7572","article-title":"ESCALADE: a phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients \u226465y with untreated non-germinal center B-cell\u2013like (non-GCB) diffuse large B-cell lymphoma (DLBCL)","volume":"39","author":"Sehn","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0057","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0058","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0059","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0060","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0061","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1038\/s41467-018-06354-3","article-title":"Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma","volume":"9","author":"Arthur","year":"2018","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0062","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0063","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0064","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0065","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1038\/sj.onc.1204640","article-title":"Dalla-Favera R mechanisms of chromosomal translocations in B cell lymphomas","volume":"20","author":"K\u00fcppers","year":"2001","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0066","doi-asserted-by":"crossref","first-page":"11816","DOI":"10.1073\/pnas.95.20.11816","article-title":"BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci","volume":"95","author":"Pasqualucci","year":"1998","journal-title":"Proc Natl Acad Sci U A"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0067","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0068","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41375-021-01251-z","article-title":"Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas","volume":"35","author":"H\u00fcbschmann","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0069","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41586-022-04906-8","article-title":"Super-enhancer hypermutation alters oncogene expression in B cell lymphoma","volume":"607","author":"Bal","year":"2022","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0070","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0071","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0072","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0073","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","article-title":"The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0074","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0075","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-020-3017-y","article-title":"Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture","volume":"589","author":"Yusufova","year":"2021","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0076","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0077","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ni.2688","article-title":"MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma","volume":"14","author":"Ying","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0078","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1084\/jem.20052204","article-title":"Inactivation of the PRDM1\/BLIMP1 gene in diffuse large B cell lymphoma","volume":"203","author":"Pasqualucci","year":"2006","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0079","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1182\/blood-2005-09-3778","article-title":"Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas","volume":"107","author":"Tam","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","article-title":"B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"52","author":"Young","year":"2015","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0081","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0082","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0083","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.17811","article-title":"Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?","volume":"196","author":"Morin","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0084","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0086","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0087","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","article-title":"Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma","volume":"8","author":"Shen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0088","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0089","doi-asserted-by":"crossref","first-page":"99237","DOI":"10.18632\/oncotarget.18502","article-title":"Comparative analysis of primary versus relapse\/refractory DLBCL identifies shifts in mutation spectrum","volume":"8","author":"Greenawalt","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0090","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","article-title":"Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas","volume":"22","author":"Morin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0091","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1186\/s12885-021-08556-3","article-title":"The mutational profile of immune surveillance genes in diagnostic and refractory\/relapsed DLBCLs","volume":"21","author":"Nesic","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0092","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/bloodadvances.2019001325","article-title":"Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series","volume":"4","author":"Wise","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0093","first-page":"432","article-title":"Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas","volume":"15","author":"Jiang","year":"2014","journal-title":"Genome Biol"},{"issue":"25","key":"10.1053\/j.seminhematol.2023.11.006_bib0094","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1200\/JCO.23.00570","article-title":"Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma","volume":"41","author":"Hilton","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0095","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0096","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0098","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0099","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1158\/0008-5472.CAN-22-3814","article-title":"Large B-cell lymphomas of immune-privileged sites relapse via parallel clonal evolution from a common progenitor B cell","volume":"83","author":"Los-de Vries","year":"2023","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.11.006_bib0100","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3324\/haematol.2020.255950","article-title":"Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma","volume":"106","author":"Isaev","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0101","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cell.2020.05.049","article-title":"TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate","volume":"182","author":"Venturutti","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.11.006_bib0102","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-22-0561","article-title":"An aged\/autoimmune B-cell program defines the early transformation of extranodal lymphomas","volume":"13","author":"Venturutti","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0103","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.2020005857","article-title":"The dangers of d\u00e9j\u00e0 vu: memory B cells as the cells of origin of ABC-DLBCLs","volume":"136","author":"Venturutti","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0104","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0105","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0106","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0107","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0108","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110713","article-title":"A single-cell atlas of diffuse large B cell lymphoma","volume":"39","author":"Ye","year":"2022","journal-title":"Cell Rep"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0110","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2326-6066.CIR-18-0439","article-title":"Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL","volume":"7","author":"Xu-Monette","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0111","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/bloodadvances.2022007493","article-title":"Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma","volume":"6","author":"Colombo","year":"2022","journal-title":"Blood Adv"},{"issue":"16","key":"10.1053\/j.seminhematol.2023.11.006_bib0112","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/bloodadvances.2023009813","article-title":"Diffuse large B-cell lymphomas have spatially-defined tumor-immune microenvironments revealed by high-parameter imaging","volume":"7","author":"Wright","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0113","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0114","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","article-title":"Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma","volume":"10","author":"Mondello","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0115","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0116","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2005-04-1510","article-title":"Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions","volume":"107","author":"Rimsza","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.11.006_bib0117","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632300094X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632300094X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:29:17Z","timestamp":1758522557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632300094X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":117,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S003719632300094X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.11.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological heterogeneity in diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}